Devonian's cash runway narrows to months as Altius revenue vanishes and pipeline remains pre-revenue
Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026
Healthcare
Page 2- Jun 29, 2026 · 20:00 · MIR · Routine +01
MedMira Reports Third Quarter Results FY2026
MedMira Reports Third Quarter Results FY2026
- Jun 29, 2026 · 08:30 · 4151 · Routine +02
Rare disease and oncology franchise delivering consistent, incremental clinical and regulatory milestones across multiple asset portfolios.
New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sezary Syndrome
- Jun 29, 2026 · 08:00 · GDAI · Neutral03
AI-driven vascular disease detection moves to public markets, but execution and commercialization remain unproven.
GuideAI Health Corp. to Begin Trading on Cboe Canada Under the Symbol "GDAI"
- Jun 29, 2026 · 07:40 · HELP · Routine +04
Helus Pharma burns cash faster in Phase 3 ramp but secures $50M runway as HLP003 nears topline readout
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
- Jun 29, 2026 · 07:16 · PCRX · Routine +05
PharmaCorp Announces Definitive Agreement to Acquire Western Canada PharmaChoice Bannered Pharmacy
PharmaCorp Announces Definitive Agreement to Acquire Western Canada PharmaChoice Bannered Pharmacy
- Jun 29, 2026 · 07:00 · ALGO · Routine +06
Pre-revenue AI diagnostics developer advances regulatory clearance for smartphone-based Strep A detection amid persistent cash burn and dilution risk.
LIGHT AI ACHIEVES ISO 13485 AND MDSAP CERTIFICATION, ADVANCING REGULATORY READINESS FOR HEALTH CANADA SUBMISSION OF QUICKSCAN(TM) SOFTWARE PLATFORM
- Jun 29, 2026 · 07:00 · DHT · Routine +07
FDA approval on schedule validates $300M Viridian thesis; milestone payment is expected cash outflow for long-dated royalty stream.
DRI Healthcare Comments on Viridian's FDA Approval and Launch of Lumvoa(TM) (veligrotug-vvze)
- Jun 29, 2026 · 07:00 · AIAI · Routine +08
NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company
NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company
- Jun 29, 2026 · 07:00 · MSCL · Material +09
Fast Track designation adds another regulatory tailwind, but clinical data in H2 2026 remains the true catalyst.
Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
- Jun 29, 2026 · 07:00 · CNVI · Routine +10
Conavi Medical Receives $1.25 Million Milestone Payment Under Ontario Life Sciences Scale-Up Fund
Conavi Medical Receives $1.25 Million Milestone Payment Under Ontario Life Sciences Scale-Up Fund
- Jun 26, 2026 · 18:29 · APLI · Routine −11
Pre-revenue biotech burns through cash, relies on distant government milestones while facing immediate going-concern liquidity crunch.
Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results
- Jun 26, 2026 · 18:00 · ONCO · Routine +12
Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
- Jun 26, 2026 · 16:15 · RVV · Routine −13
Cash-burning micro-cap biotech raises survival capital via dilutive private placement while pursuing repurposed drug for nerve agents and infectious diseases.
Revive Therapeutics Announces Proposed Private Placement
- Jun 26, 2026 · 16:11 · VIVI · Routine +14
Pioneering passive thermal protection for temperature-sensitive injectables amid aggressive global distribution expansion.
TempraMed Signs Non-Binding LOI with National Distributor in Saudi Arabia